148 related articles for article (PubMed ID: 27366930)
1. Imprinting defects in osteosarcoma: DNA- and chromatin-modifying drugs hold promise for osteosarcoma therapy.
Sarver AE; Subramanian S
Epigenomics; 2016 Jul; 8(7):885-8. PubMed ID: 27366930
[No Abstract] [Full Text] [Related]
2. An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets.
Hill KE; Kelly AD; Kuijjer ML; Barry W; Rattani A; Garbutt CC; Kissick H; Janeway K; Perez-Atayde A; Goldsmith J; Gebhardt MC; Arredouani MS; Cote G; Hornicek F; Choy E; Duan Z; Quackenbush J; Haibe-Kains B; Spentzos D
J Hematol Oncol; 2017 May; 10(1):107. PubMed ID: 28506242
[TBL] [Abstract][Full Text] [Related]
3. Imprinting defects at human 14q32 locus alters gene expression and is associated with the pathobiology of osteosarcoma.
Shu J; Li L; Sarver AE; Pope EA; Varshney J; Thayanithy V; Spector L; Largaespada DA; Steer CJ; Subramanian S
Oncotarget; 2016 Apr; 7(16):21298-314. PubMed ID: 26802029
[TBL] [Abstract][Full Text] [Related]
4. Osteosarcoma: the state of affairs dictates a change. What do we know?
Kleinerman ES; Mary V; John A
Adv Exp Med Biol; 2014; 804():vii-viii. PubMed ID: 25207354
[No Abstract] [Full Text] [Related]
5. Utilization of chromatin remodeling agents for lung cancer therapy.
Schrump DS; Hong JA; Nguyen DM
Cancer J; 2007; 13(1):56-64. PubMed ID: 17464247
[TBL] [Abstract][Full Text] [Related]
6. S-adenosylmethionine blocks osteosarcoma cells proliferation and invasion in vitro and tumor metastasis in vivo: therapeutic and diagnostic clinical applications.
Parashar S; Cheishvili D; Arakelian A; Hussain Z; Tanvir I; Khan HA; Szyf M; Rabbani SA
Cancer Med; 2015 May; 4(5):732-44. PubMed ID: 25619880
[TBL] [Abstract][Full Text] [Related]
7. Chromatin as a target for the DNA-binding anticancer drugs.
Majumder P; Pradhan SK; Devi PG; Pal S; Dasgupta D
Subcell Biochem; 2007; 41():145-89. PubMed ID: 17484128
[TBL] [Abstract][Full Text] [Related]
8. p53-dependent activation of microRNA-34a in response to etoposide-induced DNA damage in osteosarcoma cell lines not impaired by dominant negative p53 expression.
Novello C; Pazzaglia L; Conti A; Quattrini I; Pollino S; Perego P; Picci P; Benassi MS
PLoS One; 2014; 9(12):e114757. PubMed ID: 25490093
[TBL] [Abstract][Full Text] [Related]
9. Potential epigenetic therapeutics for atherosclerosis treatment.
Nicorescu I; Dallinga GM; de Winther MPJ; Stroes ESG; Bahjat M
Atherosclerosis; 2019 Feb; 281():189-197. PubMed ID: 30340764
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
Schneider-Stock R; Ocker M
IDrugs; 2007 Aug; 10(8):557-61. PubMed ID: 17665331
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic reprogramming underlies efficacy of DNA demethylation therapy in osteosarcomas.
Asano N; Takeshima H; Yamashita S; Takamatsu H; Hattori N; Kubo T; Yoshida A; Kobayashi E; Nakayama R; Matsumoto M; Nakamura M; Ichikawa H; Kawai A; Kondo T; Ushijima T
Sci Rep; 2019 Dec; 9(1):20360. PubMed ID: 31889115
[TBL] [Abstract][Full Text] [Related]
13. [Osteogenic osteosarcoma and drug therapy. Study in vitro of osteosarcoma's sensitivity to drugs. Therapeutic applications].
Morasca L; Roy-Camille R; Pouliquen JC
Chirurgie; 1970; 96(1):53-62. PubMed ID: 5279883
[No Abstract] [Full Text] [Related]
14. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.
Subbiah V; Wagner MJ; McGuire MF; Sarwari NM; Devarajan E; Lewis VO; Westin S; Kato S; Brown RE; Anderson P
Oncotarget; 2015 Dec; 6(38):40642-54. PubMed ID: 26510912
[TBL] [Abstract][Full Text] [Related]
15. Novel approaches on epigenetics.
Papait R; Monti E; Bonapace IM
Curr Opin Drug Discov Devel; 2009 Mar; 12(2):264-75. PubMed ID: 19333872
[TBL] [Abstract][Full Text] [Related]
16. Cancer stem cells in osteosarcoma.
Brown HK; Tellez-Gabriel M; Heymann D
Cancer Lett; 2017 Feb; 386():189-195. PubMed ID: 27894960
[TBL] [Abstract][Full Text] [Related]
17. The role of pharmacogenetics in the treatment of osteosarcoma.
Vos HI; Coenen MJ; Guchelaar HJ; Te Loo DM
Drug Discov Today; 2016 Nov; 21(11):1775-1786. PubMed ID: 27352631
[TBL] [Abstract][Full Text] [Related]
18. [Drug therapy of high grade osteosarcoma].
Ye T; Zhang JY; Chen J
Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(37):2893-2896. PubMed ID: 31607016
[TBL] [Abstract][Full Text] [Related]
19. EMT transcription factors: implication in osteosarcoma.
Yang G; Yuan J; Li K
Med Oncol; 2013 Dec; 30(4):697. PubMed ID: 23975634
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of the RASSF1A in osteosarcoma.
Lim S; Yang MH; Park JH; Nojima T; Hashimoto H; Unni KK; Park YK
Oncol Rep; 2003; 10(4):897-901. PubMed ID: 12792742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
